This renewal application requests funding for the 25th through 29th years of the NCI Cancer Center Support Grant of the City of Hope Comprehensive Cancer Center. The Center now has five research programs: one basic research Program (Cancer Biology, CB);three clinical/translational research Programs (Developmental Cancer Therapeutics, DCT;Cancer Immunotherapeutics, Cl;Hematologic Malignancies, HM);and one population research program (Cancer Control and Population Sciences, CCPS). Twelve shared resources support the scientific activities of the members, including two new cores (Small Animal Imaging;Clinical Immunobiology Correlative Studies Laboratory). Three developing cores are proposed (High Throughput Screening;Synthetic &Biopolymer Chemistry;Survey Research). Membership has grown by 45% in the preceding program period with the recruitment of 37 new Full Members, including several key senior leaders (Richard Jove, PhD, Deputy Director;R. Figlin, MD, Associate Director [AD] for Clinical Research). Other key leadership positions have also been filled through internal appointments (Smita Bhatia, MD, MPH, AD for Population Research;Joyce Niland, PhD, AD for Information Sciences;and Yun Yen, MD, PhD, AD for Translational Research). As a result of our program restructuring, recruitment and infrastructure development, we now believe we have a Center where our five Programs represent a continuum in which basic and translational studies in the basic science Program, CB, and one clinical Program, DCT, can be linked to Phase I and II clinical protocols in all three clinical programs (DCT, Cl, HM) and follow-up studies in survivorship and symptom management in the population sciences program (CCPS). All these activities are made possible by a Center and Institutional infrastructure that supports basic and translational research in biological and, now, small molecule approaches to cancer in an extraordinarily collaborative fashion. Such interaction has resulted in the Center's first SPORE, in lymphoma;a recent W.M. Keck Foundation award;and the renewal of eight large, multi-investigator awards. During the next funding period, we will build on these achievements so that the City of Hope Comprehensive Cancer Center takes the next step in its evolution: translating more laboratory discoveries into innovative clinical trials and developing disease-based research programs. The 82 Full Members and 90 Associate Members of the Center Programs have published 1001 articles, book chapters, etc., since the last competitive grant review. Of these, 28% are intraprogrammatic and 22% are interprogrammatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8209208
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2013-04-24
Support Year
29
Fiscal Year
2012
Total Cost
$2,225,352
Indirect Cost
$884,778
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications